NCT00711854

Randomized Clinical Trial to Compare a Regimen of Trimethoprim-sulfamethoxazole Plus Rifampicin With a Regimen of Linezolid in the Treatment of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infection

Randomized Clinical Trial to Compare a Regimen of Trimethoprim-sulfamethoxazole (TMP-SMX) Plus Rifampicin With a Regimen of Linezolid in the Treatment of Infections Caused by Methicillin-resistant Staphylococcus Aureus (MRSA)

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 150 (actual)
• Sponsor: University Hospital, Geneva · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

MRSA infections often require systemic antibiotic therapy and represent an important healthcare burden. Currently available treatment options are either only available in parenteral form (vancomycin) or expensive (linezolid). Thus, there is an urgent, unmet need to better investigate in-expensive but highly active alternatives to currently recommended standard treatment options. The purpose of the proposed study is to test the hypothesis that a combination of TMP-SMX and rifampicin is not inferior to linezolid for treatment of MRSA infections.

Conditions

• MRSA Infection

Interventions

Type	Name	Description
DRUG	trimethoprim-sulfamethoxazole (TMP-SMX)	TMP-SMX (160 mg TMP/ 800 mg SMX IV or PO 3x daily)
DRUG	Linezolid	Linezolid (600 mg IV or PO twice daily)
DRUG	Rifampicin	Rifampicin (600 mg IV or PO once daily)

Timeline

• Start date: 2009-01-01
• Primary completion: 2013-12-01
• Completion: 2014-02-01
• First posted: 2008-07-09
• Last updated: 2014-08-05

Locations

1 site across 1 country: Switzerland